From July 12th to 15th, the 2022 Misi Conference (China Medical and Health Industry Symbiosis Conference) with the theme of "Anchoring and Stable Growth" was held in Huzhou.
At the meeting, the 2021 China Pharmaceutical Industry Top 100 list was announced. With its solid R&D and production strength and stable marketing capabilities, Good Doctor Group has been shortlisted for the "Top 100 Chinese Medicine Companies in China" for four consecutive years. Ranking in the forefront, steady growth shows the style of the top 100.
It is reported that Minet has organized an expert committee of China's top 100 pharmaceutical industry rankings, relying on the database of three major terminals and six major market terminals that has been developed and operated exclusively by Minet in China for many years. The innovation driving force mainly refers to the comprehensive indicators of R&D investment of enterprises, and the professional promotion force focuses on the terminal quantitative data determined by the final selection needs of clinicians and patients, and finally selected the "Top 100 Chinese Pharmaceutical Industry in 2021" Series List" has received high attention and active participation from professional research institutions, industry experts and scholars, entrepreneurs and industry colleagues.
During the 2022 Misi Conference, the "2022 Chinese Medicine Brand List" series list was also announced simultaneously, and the Good Doctor Rehabilitation New Liquid produced by Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd. was listed on the "2022 China Medicine Brand List" (hospitals). Terminal) list, ranking second in gastrointestinal drugs.
The powerful combination of oral 5-dimensional glucose produced by Shanxi Good Doctor Pharmaceutical Co., Ltd. was listed for the first time on the list of "2022 Most Valuable Items of Chinese Chain Pharmacies", demonstrating the charm of Good Doctor's product brand.
This time, Good Doctor Group has been listed on the "Top 100 Chinese Medicine Enterprises in China" for the fourth time, and its series of products are listed on the "2022 China Pharmaceutical Brand List", which is the industry and the public's trust and quality recognition of the Good Doctor brand.
In 2021, Good Doctor Group adheres to high-quality development, takes "reform as the driving force, talent as the foundation, and innovation for development", pays attention to prevention and control, promotes production, ensures development, and seeks innovation, and handed in a heavy answer sheet : Good Doctor actively builds a smart medical network, with new development of Good Doctor's cloud medical care, Yaoyueyue, Diagnosis Baobei, and Diagnosis Professor; Good Doctor's biological raw material production and the digital intelligent factory project to expand the capacity of large varieties of Chinese patent medicines were successfully started; Gutongling tincture New strategic new products such as Dan'e Fukang Decoction were launched, and Kangfu New Liquid obtained the marketing license of Canadian natural medicines, which lived up to expectations and won the bid for centralized procurement; it promoted the vigorous development of the characteristic Chinese herbal medicine industry and fully promoted the implementation of the rural revitalization strategy.
Continuous breakthroughs in products, R&D, quality and marketing have formed core advantages. In 2021, the performance will continue to grow steadily, and the corporate brand will be increasingly consolidated.
In 2021, Good Doctor Group has won the "Top 100 Chinese Pharmaceutical Industry" for 10 consecutive years, and has been listed in the "Top 100 Chinese Pharmaceutical Manufacturing Industry", "Top 100 Private Enterprises in China for Social Responsibility", and "Top 100 Private Enterprises in Sichuan". Strong list.
It was awarded the "2021 Rural Revitalization Demonstration Case" and received more than 80 gratifying "transcripts". Chairman Geng Funeng was also awarded the honorary award of "National Advanced Individual in Poverty Alleviation".
In the future, Good Doctor will continue to focus on product quality, innovate and enhance brand value, anchor the industry trend with brand power, open up new opportunities and forge new paths in the pharmaceutical industry, achieve higher quality, more stable and sustainable development, and strive to make "Good Doctor". "Follow the road of high-quality development and go far, so that traditional Chinese medicine can be kept upright, innovative, inherited and developed.